These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29565739)

  • 1. Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain.
    Toonen LJA; Casaca-Carreira J; Pellisé-Tintoré M; Mei H; Temel Y; Jahanshahi A; van Roon-Mom WMC
    Nucleic Acid Ther; 2018 Apr; 28(2):63-73. PubMed ID: 29565739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
    Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
    Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy.
    van de Steeg E; Läppchen T; Aguilera B; Jansen HT; Muilwijk D; Vermue R; van der Hoorn JW; Donato K; Rossin R; de Visser PC; Vlaming MLH
    Nucleic Acid Ther; 2017 Aug; 27(4):221-231. PubMed ID: 28418733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
    Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
    Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates.
    Guimond A; Viau E; Aubé P; Renzi PM; Paquet L; Ferrari N
    Pulm Pharmacol Ther; 2008 Dec; 21(6):845-54. PubMed ID: 18761414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, biodistribution and safety comparison of chemically modified antisense oligonucleotides in the retina.
    Vázquez-Domínguez I; Anido AA; Duijkers L; Hoppenbrouwers T; Hoogendoorn ADM; Koster C; Collin RWJ; Garanto A
    Nucleic Acids Res; 2024 Sep; 52(17):10447-10463. PubMed ID: 39119918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
    Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
    Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice.
    Metz T; Welling MM; Suidgeest E; Nieuwenhuize E; de Vlaam T; Curtis D; Hailu TT; van der Weerd L; van Roon-Mom WMC
    Nucleic Acid Ther; 2024 Feb; 34(1):26-34. PubMed ID: 38386285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.
    González-Barriga A; Nillessen B; Kranzen J; van Kessel IDG; Croes HJE; Aguilera B; de Visser PC; Datson NA; Mulders SAM; van Deutekom JCT; Wieringa B; Wansink DG
    Nucleic Acid Ther; 2017 Jun; 27(3):144-158. PubMed ID: 28375678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of mouse 2',5'-oligoadenylate synthetase 1 paralogs.
    Elkhateeb E; Tag-El-Din-Hassan HT; Sasaki N; Torigoe D; Morimatsu M; Agui T
    Infect Genet Evol; 2016 Nov; 45():393-401. PubMed ID: 27663720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OASL-a new player in controlling antiviral innate immunity.
    Zhu J; Ghosh A; Sarkar SN
    Curr Opin Virol; 2015 Jun; 12():15-9. PubMed ID: 25676874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the RNase H cleavage kinetics and blood serum stability of the north-conformationally constrained and 2'-alkoxy modified oligonucleotides.
    Honcharenko D; Barman J; Varghese OP; Chattopadhyaya J
    Biochemistry; 2007 May; 46(19):5635-46. PubMed ID: 17411072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family.
    Eskildsen S; Justesen J; Schierup MH; Hartmann R
    Nucleic Acids Res; 2003 Jun; 31(12):3166-73. PubMed ID: 12799444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
    Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
    J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
    Chauhan NB
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):353-7. PubMed ID: 12477284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.